Financings in Brief: Boston Biomedica
This article was originally published in The Gray Sheet
Executive Summary
Boston Biomedica: Nets $12.5 mil. from Nov. 5 initial public offering of 1.6 mil. shares of common stock at $8.50 per share. Underwriters Oscar Gruss & Sons and Kaufman Bros. have an overallotment option of 240,000 additional shares. The West Bridgewater, Massachusetts maker of quality control products used with in vitro diagnostic test kits for infectious diseases will use proceeds from the offering for debt repayment, expansion of manufacturing capacity, investment in technology and other "general corporate purposes"...